Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study - Takeaways - MDSpire

Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study

  • By

  • Xue Ding

  • Zhengye Wang

  • Hong Zhang

  • Li Dai

  • Huaxing Ma

  • Guangxian Leng

  • Yunshan Yang

  • Yongjin Zhou

  • Siqi Luo

  • Qian Wang

  • Xiangren Jin

  • July 15, 2026

Share

  • 1

    The study evaluated the safety and efficacy of recombinant human adenovirus type 5 combined with the SOXP regimen in locally advanced gastric cancer.

  • 2

    A total of 25 patients were analyzed, with 32% achieving complete response and 64% achieving partial response after neoadjuvant treatment.

  • 3

    The objective response rate (ORR) was 96%, and the disease control rate (DCR) was 100%, with a pathological complete response (pCR) rate of 40%.

  • 4

    Most adverse events were mild to moderate, with no grade 4 adverse events reported, indicating a favorable safety profile for H101.

  • 5

    The study suggests that H101 combined with the SOXP regimen may enhance short-term treatment outcomes for patients with locally advanced gastric cancer.

Original Source(s)

Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study

  • by Xue Ding, Zhengye Wang, Hong Zhang, Li Dai, Huaxing Ma, Guangxian Leng, Yunshan Yang, Yongjin Zhou, Siqi Luo, Qian Wang, Xiangren Jin

  • July 15, 2026

Related Content

Translation, cultural adaptation, and psychometric validation of the Arabic version of the university of Washington quality-of-life questionnaire in Jordanian head-and-neck cancer patients

The role and signal pathways of opsin 3 in the skin: from light perception to pathophysiological mechanisms

Research progress of small molecule targeted drugs for non-small cell lung cancer